Clinical trials: Non-Cirrhotic Portal Hypertension
Portal Hypertension
Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension
Background \& Aims: Non-cirrhotic portal hypertension (NCPH) represents a relatively infrequent group of conditions. This work aimed at determining causes of NCPH and evaluating the role of some clinical, laboratory, imaging and…
- Trial name
- NCT02635815
- Testing
- Upper gastrointestinal endoscopy
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Hypertension, Portal, Interventional Radiology
Percutaneous Portal Vein Recanalization for Refractory Portal Hypertension in Children With Non-Cirrhotic Extrahepatic Portal Vein Obstruction
This monocentric, prospective, observational study aims to evaluate the clinical efficacy, safety, and technical success of percutaneous portal vein recanalization (PVR) performed via interventional radiology.
- Conditions
- Hypertension, Portal, Interventional Radiology, Percutaneous Portal Vein Recanalization (PVR), Extrahepatic Portal Vein Obstruction (EHPVO)
- Trial name
- PRIMO-01 (NCT07873021)
- Testing
- Percutaneous Portal Vein Recanalization (PVR)
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Papa Giovanni XXIII Hospital
Portal Hypertension, Budd-Chiari Syndrome
Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India
There is a need to re-evaluate the patients classified as NCPH and determine whether the new histological classification proposed by the VALDIG applies to the Indian scenario.
- Conditions
- Portal Hypertension, Budd-Chiari Syndrome, Non-Cirrhotic Portal Hypertension, Porto-Sinusoidal Vascular Diseases
- Trial name
- PSVD-India (NCT06054451)
- Where
- India
- Volunteers
- 210 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Non Cirrhotic Portal Hypertension
Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)
Background: Variceal bleeding is a major cause of morbidity and mortality in patients with Non Cirrhotic Portal Hypertension (NCPH).
- Trial name
- NCT01000779
- Testing
- Propranolol, multi band ligator for esophageal varices
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Govind Ballabh Pant Hospital
Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies
Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency
Dysimmune and specially hepatic immuno-pathological processes are frequent in patients with PIDs (primary immune deficiencies), particularly but not exclusively in patients with humoral defects.
- Conditions
- Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies, Combined Immunodeficiency (CID), Severe Combined Immunodeficiency (SCID)
- Trial name
- EVAH (NCT06659588)
- Testing
- Plasma, urine and stool collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis Liver Disease, Portal Hypertension Due to Cystic Fibrosis (Disorder)
Pre-emptive Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Cystic Fibrosis Related Liver Disease
Portal hypertension (PHT) and its sequelae are the most clinically important manifestation in cystic fibrosis related liver disease (CFLD), with end-stage liver failure as a late and rare manifestation.
- Conditions
- Cystic Fibrosis Liver Disease, Portal Hypertension Due to Cystic Fibrosis (Disorder), Portal Hypertension, Noncirrhotic
- Trial name
- NCT05037643
- Testing
- TIPS
- Volunteers
- 5 people
- Sponsor
- University Hospital, Ghent
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)